Deals
Services
Services
Corporate Finance
Tillväxtkapital
Skuldrådgivning
IPO Advisory
Equity Research
Industries
Industries
Företagstjänster
Consumer
Energy & Infrastructure
Sjuk- och hälsovård
Industri och verkstad
Software & TMT
Insights
Insights
Events
Insights
News
Newsletter
Worldwide
Worldwide
Carlsquare in North America
Carlsquare in Denmark
Carlsquare in France
Carlsquare in Germany
Carlsquare in Poland
Carlsquare in Sweden
Carlsquare in the United Kingdom
Carlsquare in North America
About Us
About Us
Om oss
Career
Offices
Team
In the Media
Kontakt
Kontakt
SV
INT
DE
Nyheter
Alla
Analysmaterial
Bolagsnyheter
Deal News
Events
I pressen
Insights
Makro och marknad
17 sep 2025
Equity Research Biosergen: Candidozyma auris on the rise in Europe
Analysmaterial
Biosergen
02 sep 2025
Research update Biosergen: Ongoing development going according to plan
Analysmaterial
Biosergen
23 maj 2025
Equity Research Biosergen: Stable quarter with exciting news around the corner
Analysmaterial
Biosergen
07 mar 2025
Research update Biosergen: Continued success in India and cash injection
Analysmaterial
Biosergen
11 feb 2025
Carlsquare Equity Research interview with Biosergen
Analysmaterial
Biosergen
14 nov 2024
Research update Biosergen: Promising interim data as BSG005 saves lives
Analysmaterial
Biosergen
23 sep 2024
Carlsquare Equity Research interview with Biosergen
Analysmaterial
Biosergen
12 sep 2024
Research update Biosergen: First patient treated in phase Ib study a success
Analysmaterial
Biosergen
05 jul 2024
Research update Biosergen: Taking the next clinical step
Analysmaterial
Biosergen
11 jun 2024
Equity Research Biosergen: Study permission received, BSG005 ready for testing in patients
Analysmaterial
Biosergen
13 mar 2024
Research update Biosergen: Rights issue to fund crucial step for lead project
Analysmaterial
Biosergen
07 mar 2024
Carlsquare Equity Research intervju med Biosergen (Engelska)
Analysmaterial
Biosergen
02 feb 2024
Equity research Biosergen: Rights issue to fund the next clinical step
Analysmaterial
Biosergen
16 jan 2024
Analys Biosergen: Licensiering till Alkem och inskickad CTA
Analysmaterial
Biosergen
08 dec 2023
Biosergen at Carlsquare Nordic life science investor day
Analysmaterial
Biosergen
16 aug 2023
Analys Biosergen, kv2 2023: lägre kostnader med förseningar i pipeline
Analysmaterial
Biosergen
29 mar 2023
Equity research Biosergen: Plans for speedy development of lead candidate
Analysmaterial
Biosergen
20 mar 2023
Initiation of coverage, Biosergen: Make antifungals great again
Analysmaterial
Biosergen